Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer

Brachytherapy

Volumn 12, Issue 5, 2013, Pages 415-421

  Parekh, Arti ^a   Chen, Ming Hui ^b   D'Amico, Anthony V ^a   Dosoretz, Daniel E ^c   Ross, Rudi ^c   Salenius, Sharon ^c   Graham, Powell L ^a   Beckman, Joshua A ^a   Beard, Clair J ^a   Choueiri, Toni K ^a   Ennis, Ronald D ^d   Hoffman, Karen E ^e   Hu, Jim C ^f   Ma, Jing ^a   Martin, Neil E ^a   Nguyen, Paul L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c 21ST CENTURY ONCOLOGY   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UCLA MEDICAL CENTER   (United States)

Author keywords

Androgen deprivation therapy; Cardiac death; Comorbidity; Diabetes; Prostate cancer

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CARDIOVASCULAR DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; HEART DISEASE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSTATE CANCER; REVASCULARIZATION;

ANDROGEN DEPRIVATION THERAPY; CARDIAC DEATH; COMORBIDITY; DIABETES; PROSTATE CANCER;

AGED; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; CAUSE OF DEATH; COMORBIDITY; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MYOCARDIAL INFARCTION; NEOADJUVANT THERAPY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 84883551997     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2013.02.005     Document Type: Article

References (18)

1. Keating N.L., O'Malley A.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006, 24:4448-4456.
2. D'Amico A.V., Denham J.W., Crook J., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007, 25:2420-2425.
3. Tsai H.K., D'Amico A.V., Sadetsky N., et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007, 99:1516-1524.
4. Levine G.N., D'Amico A.V., Berger P., et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology. CA Cancer J Clin 2010, 121:833-840.
5. U.S. Food and Drug Administration. FDA drug safety communication: Update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases. 2010. Available at: Accessed August 17,2011. http://www.fda.gov/Drugs/DrugSafety/ucm229986.htm.
6. D'Amico A.V., Manola J., Loffredo M., et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004, 292:821-827.
7. Jones C.U., Hunt D., McGowan D.G., et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011, 365:107-118.
8. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997, 337:295-300.
9. Bolla M., de Reijke T.M., Van Tienhoven G., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360:2516-2527.
10. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61:1285-1290.
11. D'Amico A.V., Chen M.H., Renshaw A.A., et al. Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA 2008, 299:289-295.
12. Piccirillo J.F., Tierney R.M., Costas I., et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004, 291:2441-2447.
13. Newgard C.D., Hedges J.R., Arthur M., et al. Advanced statistics: The propensity score-A method for estimating treatment effect in observational research. Acad Emerg Med 2004, 11:953-961.
14. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
15. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50:163-170.
16. Nguyen P.L., Je Y., Schutz F.A., et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A meta-analysis of randomized trials. JAMA 2011, 306:2359-2366.
17. Nanda A., Chen M.H., Braccioforte M.H., et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009, 302:866-873.
18. Nanda A., Chen M.H., Moran B.J., et al. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease. Eur Urol 2012, http://dx.doi.org/10.1016/j.eururo.2012.08.070.